GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting

• 81.4% of the Company’s share capital was represented at the EGM and resolutions were all unanimously approved

Regulatory News:

GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Extraordinary General Meeting (EGM) of March 18, 2024. These included among others:

• Election of two new Members of the Board of Directors, Mrs Sandrine Flory, Chief Financial Officer of Institut Mérieux, and Mr Pascal Lemaire, Chief Financial Officer of Servier
• Introduction of a variable compensation for the Board of Directors for 2023-2024, allowing to award stock options in exchange for a reduction of the fixed compensation
• Increase of the capital band and of the conditional capital, to replenish these provisions following the February 2024 capital increase.

81.42% of the Company’s share capital was represented at the AGM and resolutions were all unanimously approved. Detailed results will be available on the Company’s website at: http://www.geneuro.com/en/investors/general-meetings.

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 18 patent families protecting its technology.

For more information, visit: www.geneuro.com

Disclaimer:

This press release contains certain forward - looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240320180393/en/

GeNeuro

Jesús Martin-Garcia Chairman and CEO [phone] [e-mail]

NewCap (France)

Louis-Victor Delouvrier / Mathilde Bohin (investors) [phone] Arthur Rouillé (media) [phone] [e-mail]